STML Stemline Therapeutics, Inc.

6.80
+0.4  (6.25%)
Previous Close 6.40
Open 6.45
Price To book 1.74
Market Cap 121.35M
Shares 17,846,000
Volume 207,347
Short Ratio 1.96
Av. Daily Volume 333,874

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
High Risk Myeloproliferative Neoplasms
Phase 2 enrollment to be completed 1Q 2017. BLA filing due 2H 2017.
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2 preliminary data released November 2016.
SL-701
Second line glioblastoma (GBM) cancer
Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
Cancer- adult relapsed or refractory acute myeloid leukemia (AML)

Latest News

  1. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc.
  2. IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  3. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline - April 4, 2017
  4. 7:05 am Stemline Therapeutics provides update on its SL-401, SL-801, and SL-701 clinical programs
  5. Stemline Therapeutics Provides Update on Clinical Programs
  6. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
  7. Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Stemline Therapeutics, Inc. (STML) and Encourages Investors with Losses to Contact the Firm
  8. Lifshitz & Miller LLP Announces Investigation of Centrue Financial Corporation, Motorola Solutions, Inc., Natus Medical Incorporated, Northern Dynasty Minerals Ltd., Ocera Therapeutics, Inc., Psychemedics Corporation, RH and Stemline Therap
  9. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  10. Robbins Arroyo LLP: Stemline Therapeutics, Inc. (STML) Misled Shareholders According to a Recently Filed Class Action
  11. IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
  12. EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. Lead Plaintiff Deadline of April 4, 2017 - STML
  13. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Stemline Therapeutics, Inc. (STML) & Lead Plaintiff Deadline - April 4, 2017
  14. Stemline Investor Loss Alert: Hagens Berman Alerts Investors in Stemline Therapeutics to Expanded Class Period and Reminds Them of Lead Plaintiff Deadline
  15. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  16. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
  17. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  18. Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc.
  19. The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Stemline Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm
  20. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm